Abstract:Importance Depression is associated with alterations in blood immuno-metabolic biomarkers, but it remains unclear whether these alterations are limited to select measures or represent broader patterns and can predict depression diagnosis. Objective To examine immuno-metabolic biomarker changes in depression, pattern of effect at the symptom and symptom-dimension level, and prediction of depression diagnosis. Design, Setting, and Participants Case-control and cohort-wide analyses of ICD-10 depression, depressive and anxiety symptoms based on up to N=4161 participants (2363 female) aged 24 years from the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort. Exposures Blood-based immunological and metabolic biomarkers (n=93) comprising inflammatory proteins, cell count, lipids, hormones, and metabolites. Main Outcomes and Measures ICD-10 diagnosis of depression, 11 individual depressive and anxiety symptoms, and four domain scores were used as outcomes. Confounders included sex assigned at birth, body mass index, smoking, and alcohol use. Results After adjusting for potential confounders and multiple testing, depression was associated with changes in concentrations of specific immuno-metabolic markers (IL-6, CDCP1, neutrophil count, and insulin), and greater number of extreme-valued inflammatory markers. We identified three distinct affective symptom-related biomarker clusters, including one comprising inflammatory cytokines, chemokines and cells which was positively associated with somatic and mood symptoms, and one comprising liver-related biomarkers which was negatively associated with anxiety symptoms. Then using Partial Least Squares regression we identified two latent variables that capture the biomarker-symptom associations (Component 1: Somatic-Depressive-Inflammation and Component 2: Anxiety-Hepatic). Higher Component 1 score was associated with higher depressive symptom severity consistently over subsequent five years. Immuno-metabolic biomarkers performed poorly in predicting ICD-10 depression (0.569 Balanced Accuracy). However, within depression cases the addition of immuno-metabolic biomarkers improved the prediction of depression with high levels of mood (0.720 Balanced Accuracy) or anxiety symptoms (0.636 Balanced Accuracy). Conclusion and Relevance Depression is associated with disruption in immuno-metabolic homeostasis. Specific patterns of immuno-metabolic biomarkers are associated with differing subsets of affective symptoms, which are potentially relevant for poor depression prognosis. Immuno-metabolic biomarkers improve predictions of high levels of mood symptoms within people with depression, highlighting the symptom-level heterogeneity of depression and opportunities for immuno-metabolic biomarker-based subtyping, prediction, and targeted intervention.

Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Serum proteomic analysis uncovers novel serum biomarkers for depression

Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents

Potential major depressive disorder biomarkers in pediatric population - a pilot study

Identification of Key Modules and Genes Associated with Major Depressive Disorder in Adolescents

Background data for the identification of protein biomarkers in CSF by proteomic approaches

Plasma Proteomics Identifies Proteins and Pathways Associated with Incident Depression in 46,165 Adults

Distinct proteomic profiles in prefrontal subareas of elderly major depressive disorder and bipolar disorder patients

A single-nucleus transcriptome-wide association study implicates novel genes in depression pathogenesis

Identification and Analyses of Crucial Genes Associated with Pathogenesis of Major Depressive Disorder

Identification of Potential Biomarkers for Major Depressive Disorder: Based on Integrated Bioinformatics and Clinical Validation

Peripheral Blood Mononuclear Cell Biomarkers for Major Depressive Disorder: A Transcriptomic Approach

Distinct Proteomic Profiles in Prefrontal Subareas of Major Depressive Disorder and Bipolar Disorder Patients

Neurodevelopmental signature of a transcriptome-based polygenic risk score for depression

Key Risk Genes Identified From the Postmortem Brain of Patients With Major Depressive Disorder and Their Potential Clinical Applications

Identifying clinical and proteomic markers for early diagnosis and prognosis prediction of major psychiatric disorders

Cohort profile: BioMD-Y (biopsychosocial factors of major depression in youth) - a biobank study on the molecular genetics and environmental factors of depression in children and adolescents in Munich

Screening and identification of key biomarkers of depression using bioinformatics

Unraveling the transcriptomic signatures of Parkinson's disease and major depression using single-cell and bulk data

Blood Immuno-metabolic Biomarker Signatures of Depression and Affective Symptoms in Young Adults